Antihypertensive effects of crude extracts from leaves of Echinodorus grandiflorus

The antihypertensive action of a crude ethanolic extract (EEEG) from leaves of Echinodorus grandiflorus (Alismataceae) was investigated in spontaneously hypertensive rats. The intraperitoneal injection of increasing doses of EEEG (300–1000 mg/kg) elicited dose‐dependent reductions in mean arterial pressure (MAP) that were paralleled by reductions of cardiac output and systemic vascular resistance, reaching the maximum of 23 ± 5%, 13 ± 3% and 18 ± 4%, respectively (n = 5, P < 0.05). Comparable reductions of MAP were obtained upon i.v. administration of EEEG (3–100 mg/kg), reaching the maximum decrease of 51 ± 6% (n = 7; P < 0.001). The blockade of nitric oxide synthesis significantly reduced the hypotension induced by i.v. administration of EEEG. Moreover, the pre‐treatment of the animals with a selective antagonist of cholinergic muscarinic receptors or of platelet‐activating factor (PAF) receptors partially blunted the cardiovascular effects of EEEG. The i.v. pre‐treatment with the selective B2 bradykinin receptor antagonist HOE 140 or with indomethacin, an inhibitor of the enzyme cyclooxygenase, did not prevent the hypotensive effects induced by EEEG. Finally, the chronic oral treatment with EEEG presented a significant antihypertensive effect that was comparable to that of reference antihypertensive drugs currently used to treat arterial hypertension. It is concluded that EEEG elicits significant acute antihypertensive effects through the release of nitric oxide and the stimulation of cholinergic muscarinic and PAF receptors. Moreover, our results suggest that EEEG may be appropriate to chronic oral treatment of arterial hypertension.

[1]  M. A. Kaplan,et al.  Pharmacological mechanisms involved in the vasodilator effects of extracts from Echinodorus grandiflorus. , 2007, Journal of ethnopharmacology.

[2]  J. Tuomilehto,et al.  Trends in the prevalence, awareness, treatment and control of hypertension: the WHO MONICA Project , 2006, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[3]  J. Whitworth,et al.  2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension , 2003, Journal of hypertension.

[4]  K. Kimura,et al.  Local Variation in the Content of Angiotensin II and Arginine Vasopressin Receptor Antagonistic Terpenoids in the Rhizomes of Alisma orientale , 2002, Planta medica.

[5]  J. Kobayashi,et al.  Echinodolides A and B, new cembrane diterpenoids with an eight-membered lactone ring from the leaves of Echinodorus macrophyllus. , 2002, Journal of natural products.

[6]  J. Kobayashi,et al.  Echinophyllins C-F, new nitrogen-containing clerodane diterpenoids from Echinodorus macrophyllus. , 2000, Journal of natural products.

[7]  J. Kobayashi,et al.  Chapecoderins A-C, new labdane-derived diterpenoids from Echinodorus macrophyllus. , 2000, Journal of natural products.

[8]  J. Calixto,et al.  Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). , 2000, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[9]  R. Lopes-Martins,et al.  Involvement of platelet-activating factor in the modulation of vascular tone in the isolated perfused rabbit kidney , 1999, Naunyn-Schmiedeberg's Archives of Pharmacology.

[10]  R. Lopes-Martins,et al.  The acute increases in vasomotor tone and blood pressure induced by carotid artery occlusion are modulated by platelet-activating factor (PAF) independently of nitric oxide release. , 1997, Journal of lipid mediators and cell signalling.

[11]  R. Busse,et al.  Endothelial dysfunction in atherosclerosis. , 1996, Journal of vascular research.

[12]  C. Thiemermann,et al.  Role for intracellular platelet‐activating factor in the circulatory failure in a model of Gram‐positive shock , 1995, British journal of pharmacology.

[13]  M. Rola-Pleszczynski,et al.  Role of R‐type calcium channels in the response of the perfused arterial and venous mesenteric vasculature of the rat to platelet‐activating factor , 1994, British journal of pharmacology.

[14]  J. Filep,et al.  Modulation by nitric oxide of platelet‐activating factor‐induced albumin extravasation in the conscious rat , 1993, British journal of pharmacology.

[15]  R. Hartmann,et al.  Echinodol: A New Cembrene Derivative from Echinodorus grandiflorus , 1993, Planta medica.

[16]  L. Juncos,et al.  Vasodilator and constrictor actions of platelet-activating factor in the isolated microperfused afferent arteriole of the rabbit kidney. Role of endothelium-derived relaxing factor/nitric oxide and cyclooxygenase products. , 1993, The Journal of clinical investigation.

[17]  H. Moritoki,et al.  Nitric oxide synthase responsible for l‐arginine‐induced relaxation of rat aortic rings in vitro may be an inducible type , 1992, British journal of pharmacology.

[18]  K. Kamata,et al.  Endothelium‐dependent vasodilator effects of platelet activating factor on rat resistance vessels , 1989, British journal of pharmacology.

[19]  H. Matsuda,et al.  Effects of alismol isolated from Alismatis Rhizoma on calcium-induced contraction in the rabbit thoracic aorta. , 1987, Life sciences.

[20]  L. Touqui,et al.  Perspectives in platelet-activating factor research. , 1987, Pharmacological reviews.

[21]  K. Weber,et al.  Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. , 1987, The Journal of pharmacology and experimental therapeutics.

[22]  J. P. Gilmore,et al.  Influence of kallidin-10 on renal function , 1964 .

[23]  E. Faraco,et al.  General Circulatory Alterations Induced by Intravenous Infusion of Synthetic Bradykinin in Man , 1964, Circulation.

[24]  H. Kawasaki,et al.  Endothelium-dependent relaxant action of platelet activating factor in the rat mesenteric artery , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[25]  E. Schapoval,et al.  Ethnopharmacological studies of antimicrobial remedies in the south of Brazil. , 2004, Journal of ethnopharmacology.

[26]  S. Moncada,et al.  Inhibition of nitric oxide synthase as a potential therapeutic target. , 1999, Annual review of pharmacology and toxicology.

[27]  J. N. Sharma,et al.  Blood pressure regulation by the kallikrein-kinin system. , 1996, General pharmacology.

[28]  H. Matsuda,et al.  The effect of alismol isolated from alismatis rhizoma on experimental hypertensive models in rats , 1989 .

[29]  M. Leider Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .

[30]  Flávio Maciel de Freitas,et al.  General Circulatory Alterations Induced by Intravenous Infusion of Synthetic Bradykinin in Man , 1964 .

[31]  J. P. Gilmore,et al.  INFLUENCE OF KALLIDIN-L0 ON RENAL FUNCTION. , 1964, The American journal of physiology.